When randomized 50/50 this automatically reduces imatinib's MMR by half, or 10%, versus Pona. This also increases Pona's MMR by 7.5% since 75% of T315I patients achieved MMR in PACE trial.
So automatic 17.5% delta on MMR, and as you say throw in a few more of the 49 additional mutations shown to be resistant to imatinib but sensitive to Ponatinib and voila...its EPIC!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.